NATIONAL HEALTHCARE CORP Posts Higher Year-Over-Year Revenue, Operating Income, Net Income, and Diluted EPS Across Both the Quarter and the Six-Month Year-to-Date Period

Bottom line

For the period-ended-2026-06-30 filed by NATIONAL HEALTHCARE CORP under accession 0001437749-26-026199 on 10-Q, the interim condensed consolidated statements present higher year-over-year results on every headline line for both the three-month reporting period and the six-month year-to-date period. Revenues for the six months ended June 30, 2026 are reported in USD and were higher than the prior-year comparative for the six months ended June 30, 2025; the quarter line follows the same direction, with the three months ended June 30, 2026 higher than the three months ended June 30, 2025. Operating Income (Loss) moves in the same direction, reported as a profit for the current the three months ended June 30, 2026 and the six months ended June 30, 2026 versus a profit in each prior-year comparative, preserving the profit-to-profit transition in both periods. Net Income (Loss) Attributable to Parent is also a profit in each period presented and is higher than the prior-year comparative on both the quarter and the six-month year-to-date basis, again with no transition out of profitability. Earnings Per Share, Diluted is reported in USD/SHARES and is higher year over year in both the quarter and the six-month year-to-date period, remaining in profit territory versus the prior-year comparatives.

Management explains in Note 1 and Note 2 that the interim statements are prepared on the same GAAP basis as the audited December period financials, that all normal recurring adjustments necessary for a fair presentation have been recorded, and that net patient revenues and other revenues are recognized as performance obligations are satisfied under the policies described in those notes. The filing evidence does not attribute this change to any single cause.

The source scope for this section is limited to the interim condensed consolidated financial statements and accompanying notes attached to the 10-Q filed under 0001437749-26-026199 (CIK 0001047335; ticker NHC). The filing evidence does not disclose segment-level detail for these headline dimensions, and no peer or industry comparison is presented in the filing itself. The interim results are not necessarily indicative of a full year, as management notes in Note 2. The dimension of The filing evidence does not disclose segment-level detail for this dimension. is therefore not addressed, and The filing evidence contains no peer or industry comparison. is acknowledged.

Analyst inference in this section is restricted to the authorized year-over-year comparisons listed above; no independent calculation of growth, margin, or gap is offered, because no digit may be introduced in this prose. Counter-evidence is also absent from the package: no restatement, no qualification, and no contrary period are presented in the cited notes, and the Note 1 business description frames the Company as a multi-state senior-care and related-services operator without flagging any discontinuity. Unknowns that remain open for later sections include the composition of the revenue increase between net patient revenues and other revenues, any acquisition contribution referenced in Note 3, and segment performance discussed under Note 7, none of which is resolved by the headline figures cited here.

The single relevant cross-publisher insight available in the inventory, Heritage Financial Posts Higher Year-Over-Year Diluted EPS and Net Income on Both the Quarter and the Six-Month Year-to-Date Period, illustrates a comparable pattern of higher diluted EPS and net income across both periods at a different filer; it is referenced only as a parallel example of the same direction, not as evidence about NHC.

Financial performance

- For the three-month reporting period, Revenues were higher than the prior-year quarter, and the authorized direction for the year-over-year move was upward. - For the six-month year-to-date period, Revenues were higher than the prior-year comparative, again with an authorized upward direction. - Operating Income (Loss) was positive for both the current three-month period and the prior-year quarter, and the authorized year-over-year direction was upward; the same shape holds for the six-month year-to-date period, with a profit in both periods and an authorized upward direction.

- Net Income (Loss) Attributable to Parent was a profit in the current three-month period and a profit in the prior-year quarter, with an authorized upward year-over-year direction; the six-month year-to-date shows a profit in both periods and an authorized upward direction. - Earnings Per Share, Diluted was positive in both the current three-month period and the prior-year quarter, with an authorized upward year-over-year direction; the six-month year-to-date shows positive EPS in both periods and an authorized upward direction.

- Management explains the revenue recognition context in the cited notes: net patient revenues are reported at the amount the Company expects to be entitled to in exchange for patient services, with variable consideration constrained and adjusted when actual settlements differ; this is the basis for the revenue lines shown above. - Management also notes that, in the second quarter, previously unrecorded management fees tied to services rendered before a recent transaction became recognizable upon the acquisition of five skilled nursing facilities from National Health Corporation, as referenced in the cited acquisition note; this is the company-stated reason that those management fees appeared in the current period's results.

- The Company describes two reportable operating segments under the cited segment-reporting framework — inpatient services and homecare and hospice services — plus an "all other" category that bundles rental income, management and accounting services fees, insurance services, and corporate office costs. S. GAAP, the recognition of routine services as a single performance obligation satisfied over time, ancillary services recognized at a point in time, the use of the expected value method for variable consideration, and the recognition of insurance premiums over the policy period.

- The filing evidence does not attribute the quarter-to-quarter change to any single cause beyond the management-fee recognition event explicitly disclosed. For the broader revenue, operating income, net income, and EPS movements, The filing evidence does not attribute this change to any single cause.. - Management provides no forward guidance in the cited notes or other quoted context; expectations for upcoming periods are not stated, and the filing evidence does not lay out a quantitative outlook, so forward-looking expectation commentary is limited to describing what was and was not disclosed.

- The filing evidence contains no peer or industry comparison. — the filing does not include peer or industry benchmarks, so no external comparison baseline can be drawn from the filing evidence. - Readers comparing this interim with other healthcare interim filings can cross-check the year-over-year pattern in another healthcare provider's disclosure such as Ralph Lauren Reports Higher Year-Over-Year Revenue, Operating Income, Net Income, and Diluted EPS in Interim Filing, which uses a similar upward direction across the same four lines, to see how the headline metrics compare in shape only — not in magnitude.

Operating drivers and segments

- For the three-month reporting period, the Company reported Revenues of $408,025,000 USD and Operating Income of $48,935,000 USD, a profit on both the top line and the operating line, against prior-period Revenues of $374,910,000 USD and Operating Income of $34,090,000 USD. - For the six-month year-to-date period, the Company reported Revenues of $789,846,000 USD and Operating Income of $81,188,000 USD, against prior-period Revenues of $748,607,000 USD and Operating Income of $64,857,000 USD; both periods were profitable.

- The segment architecture disclosed in Note 7 references reportable operating segments, but the quoted excerpt summarized here does not enumerate segment names or split the operating result between them; what is shown is a single consolidated revenue and operating result rather than a segment-by-segment margin table. - Net patient revenues, per the revenue-recognition policy in Note 1, are described as derived from skilled and intermediate nursing, rehabilitation therapy, assisted living, independent living, home health, hospice, and behavioral health services, with variable consideration constrained to the extent that a significant reversal is not probable; the related accounting-policy reference is Note 2.

- Management frames the Company, in Note 1, as a leading provider of senior health-care services operating specialized care units such as Alzheimer's and sub-acute nursing units, and additionally providing insurance services, management and accounting services, and property leases to operators of skilled nursing and assisted living facilities across the southeastern United States. - Management represents revenue recognition in Note 1 as performance-obligation-based, treating routine services as a single obligation satisfied over time and treating ancillary services as point-in-time obligations, with the transaction price determined from contractually agreed amounts adjusted for variable consideration under the expected value method.

- Management flags, in Note 1, that the interim financial information is not necessarily indicative of full-year results and that actual outcomes could differ from estimates in a manner that causes reported net income to vary significantly from period to period. - The interim disclosure also cites Note 3, relating to an acquisition of five skilled nursing facilities, as part of the period's reported activity, although the excerpt does not detail the contribution of those facilities to the revenue or operating result.

- Management references a recently issued ASU on disaggregation of income-statement expenses that will require additional expense-line disclosure in future filings, with no impact narrated for the current period.

Cash flow and capital

Reported facts (cash flow statement): - Net Cash Provided by (Used in) Operating Activities was $102,074,000 USD for the prior-year comparative six-month year-to-date period and $105,802,000 USD for the six months ended June 30, 2026, with the authorized year-over-year direction for operating cash flow being an increase on a positive base in both periods. - Net Cash Provided by (Used in) Investing Activities was -$22,902,000 USD for the prior-year comparative six-month year-to-date period and -$101,557,000 USD for the six months ended June 30, 2026, with the authorized year-over-year direction being a decrease on a negative base in both periods. - Net Cash Provided by (Used in) Financing Activities was -$45,732,000 USD for the prior-year comparative six-month year-to-date period and -$64,154,000 USD for the six months ended June 30, 2026, with the authorized year-over-year direction being a decrease on a negative base in both periods.

Management explanation and accounting policy: The narrative section covering long-term leases, property and equipment, investments in unconsolidated companies, business combinations, goodwill, accrued risk reserves, and continuing care contracts describes the Company's measurement policies but does not reconcile the year-over-year movements in the three cash flow captions. No management commentary is quoted in the filing evidence attributing the operating, investing, or financing cash flow changes to specific drivers. For that reason, this analysis treats the directional contrasts as reported and does not assign causes. The filing evidence does not attribute this change to any single cause.

Capital allocation components (reported): - Payments to Acquire Property, Plant, and Equipment were $16,341,000 USD in the prior-year comparative six-month year-to-date period and $22,167,000 USD in the six months ended June 30, 2026, with the authorized year-over-year direction being an increase on a positive base in both periods. - Payments for Repurchase of Common Stock were $6,384,000 USD in the prior-year comparative six-month year-to-date period and $23,561,000 USD in the six months ended June 30, 2026, with the authorized year-over-year direction being an increase on a positive base in both periods. - Payments of Ordinary Dividends, Common Stock were $18,854,000 USD in the prior-year comparative six-month year-to-date period and $19,930,000 USD in the six months ended June 30, 2026, with the authorized year-over-year direction being an increase on a positive base in both periods.

Analyst inference and counter-evidence: Read together, the authorized directional set suggests a year-over-year posture in which the operating cash line moves higher on a positive base while the investing and financing cash lines become more negative; capital allocation through property, plant and equipment, share repurchases, and ordinary dividends is authorized to rise versus the prior-year comparative. The counterweight in the picture is that long-term debt, excluding current maturities, is reported at $0 USD on the balance sheet date of June 30, 2026, with an authorized direction of zero, which on its face does not point to incremental long-term borrowing as the engine behind the higher authorized outflows. Because the filing pairs the negative financing direction with rising authorized dividends and buybacks on a positive base, the read-through is that shareholder-return and capex activity are crowding into financing and investing uses rather than being funded through a higher long-term debt balance at the balance sheet date.

Balance sheet position (reported): - Cash and Cash Equivalents, at Carrying Value stood at $39,209,000 USD as of the balance sheet date of June 30, 2026. - Long-term Debt, Excluding Current Maturities stood at $0 USD as of the balance sheet date of June 30, 2026, with an authorized direction of zero relative to the prior comparable balance.

Unknowns: - The filing evidence contains no peer or industry comparison for these cash flow and capital allocation lines. The filing evidence contains no peer or industry comparison. - The filing evidence does not disclose segment-level detail for operating, investing, or financing cash flow, for capital expenditures, or for the shareholder-return lines. The filing evidence does not disclose segment-level detail for this dimension.

Peer and historical context

Within NATIONAL HEALTHCARE CORP's 10-Q for period-ended-2026-06-30 (accession 0001437749-26-026199, CIK 0001047335, ticker NHC), the year-over-year picture across the catalog's four headline dimensions moves in the direction the machine has authorized, and the directional shape of that picture is the only narrative the filing evidence supports.

On a year-to-date basis through the six months ended June 30, 2026, Revenues moved higher than the the six months ended June 30, 2025 comparative, as captured by $748,607,000 and $789,846,000. The same direction holds at the three-month slice: Revenues for the three months ended June 30, 2026 were higher than the the three months ended June 30, 2025 figure reported as $374,910,000 and $408,025,000. Operating Income (Loss) likewise moved higher against its prior-year benchmark in both windows, with the half-year figure $81,188,000 above $64,857,000 and the quarter figure $48,935,000 above $34,090,000. Net Income (Loss) Attributable to Parent followed the same path on both horizons, comparing $55,927,000 to $76,176,000 and $23,722,000 to $40,319,000, with each transition recorded as profit to profit. The half-year cash-flow line tracked the same direction, with Net Cash Provided by (Used in) Operating Activities at $105,802,000 higher than the prior-year figure $102,074,000. Earnings Per Share, Diluted is authorized as rising on both the half-year and quarter comparisons, consistent with the profit-to-profit transition recorded for net income.

Taken together, the catalog allows the conclusion that every measured operating and profitability line expanded against its prior-year benchmark in both the three-month and six-month reporting windows, with no line in the catalog showing a contraction or a transition from profit to loss. The pattern of synchronized gains across revenue, operating income, and net income — together with stronger operating cash flow — is the kind of configuration that, for unrelated issuers such as the one profiled in Heritage Financial Posts Higher Year-Over-Year Diluted EPS and Net Income on Both the Quarter and the Six-Month Year-to-Date Period, tends to attract attention precisely because the directional signal is clean across multiple dimensions in the same reporting cycle.

The catalog does not support, and this section does not attempt to derive, any explanation for the magnitude of those movements; the filing's narrative in Note 2 and Note 3 does not isolate a single driver of revenue or income, and broader industry or peer benchmarks are not part of the filing evidence. The filing evidence does not attribute this change to any single cause.

A direct peer or sector comparison is not possible from the supplied facts: the catalog exposes only this issuer's prior-year comparatives, not a matched set of skilled-nursing, assisted-living, or CCRC operators. The filing evidence contains no peer or industry comparison. Likewise, segment-level results for the long-term care, home health, and ancillary lines described in Note 7 are not surfaced as separate quantitative dimensions in this section's catalog, so a within-portfolio comparison of how each segment contributed to the consolidated gains cannot be reconstructed. The filing evidence does not disclose segment-level detail for this dimension. A historical comparison across earlier fiscal years is similarly out of scope, because the catalog's prior-year comparatives extend back only one year for each reporting window.

Scenario analysis

- Reported facts for NATIONAL HEALTHCARE CORP (NHC, 10-Q for period-ended-2026-06-30, accession 0001437749-26-026199): Revenues were $408,025,000 USD for the three months ended June 30, 2026 and $789,846,000 USD for the six months ended June 30, 2026, each higher than the prior-year comparatives of $374,910,000 USD and $748,607,000 USD respectively (the reported Revenues comparison permits this direction). - Net Income (Loss) Attributable to Parent was $40,319,000 USD for the three months ended June 30, 2026 and $76,176,000 USD for the six months ended June 30, 2026, each higher than the prior-year comparatives of $23,722,000 USD and $55,927,000 USD respectively (the reported Net Income comparison permits this direction). - Management explanations referenced in Note 2 discuss continuing-care contracts, external actuarial estimation of claims exposure, and the possibility that future events could cause significant adjustments to reserve estimates and cause reported net income to vary significantly from period to period. - Analyst inference: a base reading is that top-line and bottom-line both moved in the same authorized direction across both the quarter and the year-to-date period, with the narrative offering no single quantified driver. - Counter-evidence: none within the filing; the source narrative flags uncertainty around claims reserves and CCRC obligation re-measurement, which can move net income independently of revenue. - Unknowns: the specific magnitude of the revenue or earnings change and any segment-level breakdown — the filing evidence does not quantify them and The filing evidence does not attribute this change to any single cause..

- Reported facts: the same Revenues and Net Income figures above were both higher than their prior-year comparatives on a quarter and year-to-date basis (authorized direction). - Management explanations: Note 3 describes the acquisition of five skilled nursing facilities from the affiliate National Health Corporation, framed as an operational expansion into additional states and a strategic advancement within the existing footprint, with preliminary purchase-price allocation work referenced. - Analyst inference: an upside reading leans on the acquisition narrative in Note 3 together with the authorized year-over-year revenue and earnings increases, while still acknowledging that the filing does not isolate how much of the increase came from the acquired facilities versus the legacy base. - Counter-evidence: Note 2 explicitly warns that reserve revisions could cause reported net income to vary significantly, and the CCRC obligation re-measurement language can produce an offsetting charge. - Unknowns: the acquired-facility contribution to revenue and earnings is not separately quantified in the filing evidence; The filing evidence contains no peer or industry comparison. applies for any cross-issuer comparison, while the prior-year context shown in Heritage Financial Posts Higher Year-Over-Year Diluted EPS and Net Income on Both the Quarter and the Six-Month Year-to-Date Period is a separately filed peer observation, not a benchmark inside this report.

- Reported facts: the authorized Revenues and Net Income comparisons both read as increases against the prior year, so the downside here is framed around risk language rather than an authorized negative move. - Management explanations: Note 2 highlights rising personal-injury and wrongful-death claims activity in the long-term care industry, the use of an external actuary for claims-obligation estimation, and the possibility of significant reserve adjustments. - Analyst inference: a downside reading treats the authorized increases as the starting point but notes that claims-reserve true-ups, CCRC obligation re-measurement, and the still-pending evaluation of the disaggregation ASU referenced in Note 2 could each independently alter reported net income in a later period. - Counter-evidence: no filing line contradicts the authorized direction; the downside rests on disclosed risk language, not on a recorded decline. - Unknowns: the size of any reserve adjustment and the timing of any future obligation change are not quantified; The filing evidence does not attribute this change to any single cause. for any specific cause.

Risks and what to watch

- Reported facts: The interim condensed consolidated statements of operations present Revenues of $408,025,000 for the three months ended June 30, 2026 and $789,846,000 for the six months ended June 30, 2026, with prior-period comparatives of $374,910,000 and $748,607,000; the same filing also reports Net Income (Loss) Attributable to Parent of $40,319,000 and $76,176,000 versus $23,722,000 and $55,927,000. - Management explanations: Management describes the Note 3 transaction as both an expansion of NHC's operations into South Carolina and Tennessee and a strategic advancement of its growth in its existing operational footprint, and notes that a preliminary purchase price allocation is in progress across widely accepted income-based, market-based, and cost-based valuation approaches.

The accounting-policies narrative in the cited note also flags that the Company is currently evaluating the impact of the disaggregation-of-expenses ASU on its financial statements. - Analyst inference: Because the authorized comparisons state that Revenues and Net Income (Loss) Attributable to Parent moved higher for both the three-month reporting period and the six-month year-to-date period on a year-over-year basis, while the operating-income, diluted EPS, financing-activity, investing-activity, operating-activity, repurchase, ordinary-dividend, and capital-expenditure authorized comparisons describe other directions for the six-month year-to-date period, the next period should be read as a confirmation of whether the revenue and earnings step-up holds after the acquisition is consolidated for a full reporting window.

Readers comparing interim healthcare-services results can cross-check the pattern against Heritage Financial Posts Higher Year-Over-Year Diluted EPS and Net Income on Both the Quarter and the Six-Month Year-to-Date Period for a contrasting bank-centric profile. - Counter-evidence: The interim filing makes clear that the purchase price allocation for the five skilled nursing facilities described in Note 3 is preliminary, which means reported goodwill, intangibles, and any related amortization or depreciation recognized through Other Operating Expense referenced in Note 7 could shift in subsequent periods as the valuation work is finalized; this creates a clean-sheet risk to next period's operating-income and earnings lines.

; the filing evidence does not attribute this change to any single cause. ; the filing evidence contains no peer or industry comparison. The interim filing's Part II cover-page sections (Item 1, Item 1A, Item 2, Item 3, Item 4, Item 5, and Item 6) and the description-of-business disclosure in Note 1 and Note 2 do not surface any new legal-proceeding or risk-factor amendment for this section to weigh against the reported results, so any incremental litigation, regulatory, or reimbursement-policy exposure remains unstated in the cited evidence.

- Metrics to watch next period: track Revenues and Net Income (Loss) Attributable to Parent to confirm the year-over-year step-up for both reporting windows; monitor Operating Income to verify that the higher top line translates into a higher operating result; review Net Cash Provided by (Used in) Operating Activities, Payments to Acquire Property, Plant, and Equipment, Payments for Repurchase of Common Stock, and Payments of Ordinary Dividends, Common Stock to gauge how the cash return and capex cadence evolve alongside the acquisition; and watch for completion of the Note 3 purchase price allocation and the Company's evaluation of the disaggregation-of-expenses ASU as potential restatement or reclassification triggers.